$SLXP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SALIX PHARMACEUTICALS LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SALIX PHARMACEUTICALS LTD. Get notifications about new insider transactions in SALIX PHARMACEUTICALS LTD for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | D | 173.00 | 48,006 | 8,305,038 | 0 | 48 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | U | 173.00 | 26,956 | 4,663,388 | 0 | 27 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | President, Medical, ... | Sell | D | 173.00 | 51,714 | 8,946,522 | 0 | 51.7 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Option Exercise | D | 17.63 | 15,000 | 264,450 | 0 | |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Sell | U | 173.00 | 6,500 | 1,124,500 | 0 | 6.5 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Sell | U | 173.00 | 260 | 44,980 | 0 | 260 to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Sell | U | 173.00 | 1,080 | 186,840 | 0 | 1.1 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Sell | U | 173.00 | 10,450 | 1,807,850 | 0 | 10.5 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Sell | D | 173.00 | 21,032 | 3,638,536 | 0 | 21 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting President an ... | Sell | U | 173.00 | 74,555 | 12,898,015 | 0 | 74.6 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | CREECH TIMOTHY J | See Remarks | Sell | D | 173.00 | 21,372 | 3,697,356 | 0 | 21.4 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | CREECH TIMOTHY J | See Remarks | Sell | U | 173.00 | 4,065 | 703,245 | 0 | 4.1 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Option Exercise | D | 17.63 | 15,000 | 264,450 | 0 | |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Sell | D | 173.00 | 6,370 | 1,102,010 | 0 | 6.4 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Sell | U | 173.00 | 32,790 | 5,672,670 | 0 | 32.8 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Bertrand William C JR | See Remarks | Sell | D | 173.00 | 28,289 | 4,893,997 | 0 | 28.3 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Bertrand William C JR | See Remarks | Sell | U | 173.00 | 2,969 | 513,637 | 0 | 3 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | D | 173.00 | 28,644 | 4,955,412 | 0 | 28.6 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | D | 173.00 | 294,120 | 50,882,760 | 0 | 294.1 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | D | 173.00 | 6,370 | 1,102,010 | 0 | 6.4 K to 0 (-100.00 %) |
Apr 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | U | 173.00 | 31,057 | 5,372,861 | 0 | 31.1 K to 0 (-100.00 %) |
Mar 13 2015 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Gift | G | 0.00 | 600 | 0 | 39,160 | 39.8 K to 39.2 K (-1.51 %) |
Mar 11 2015 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | President, Medical ... | Sell | S | 157.84 | 42,880 | 6,768,179 | 51,714 | 94.6 K to 51.7 K (-45.33 %) |
Mar 09 2015 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | S | 157.55 | 4,000 | 630,200 | 74,962 | 79 K to 75 K (-5.07 %) |
Mar 09 2015 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 157.96 | 20,000 | 3,159,200 | 94,594 | 114.6 K to 94.6 K (-17.45 %) |
Mar 09 2015 | SLXP | SALIX PHARMACEUTIC ... | CREECH TIMOTHY J | See Remarks | Sell | S | 157.67 | 4,600 | 725,269 | 25,437 | 30 K to 25.4 K (-15.31 %) |
Mar 09 2015 | SLXP | SALIX PHARMACEUTIC ... | CREECH TIMOTHY J | See Remarks | Gift | G | 0.00 | 500 | 0 | 30,037 | 30.5 K to 30 K (-1.64 %) |
Feb 04 2015 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Acting Chief Execut ... | Grant | A | 0.00 | 14,662 | 0 | 95,587 | 80.9 K to 95.6 K (+18.12 %) |
Feb 03 2015 | SLXP | SALIX PHARMACEUTIC ... | Bertrand William C JR | See Remarks | Grant | A | 0.00 | 2,851 | 0 | 31,258 | 28.4 K to 31.3 K (+10.04 %) |
Jan 08 2015 | SLXP | SALIX PHARMACEUTIC ... | CREECH TIMOTHY J | See Remarks | Payment of Exercise | F | 114.94 | 3,248 | 373,325 | 30,537 | 33.8 K to 30.5 K (-9.61 %) |
Jan 08 2015 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 114.94 | 10,997 | 1,263,995 | 114,594 | 125.6 K to 114.6 K (-8.76 %) |
Jan 08 2015 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 114.94 | 8,408 | 966,416 | 78,962 | 87.4 K to 79 K (-9.62 %) |
Dec 23 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 17.63 | 44,000 | 775,720 | 0 | |
Dec 23 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 17.63 | 44,000 | 775,720 | 703,838 | 659.8 K to 703.8 K (+6.67 %) |
Nov 26 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Option Exercise | M | 17.63 | 15,000 | 264,450 | 0 | |
Nov 26 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Buy | M | 17.63 | 15,000 | 264,450 | 294,120 | 279.1 K to 294.1 K (+5.37 %) |
Nov 14 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.63 | 6,250 | 110,188 | 0 | |
Nov 14 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 11,200 | 196,336 | 0 | |
Nov 14 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 95.05 | 11,079 | 1,053,059 | 125,591 | 136.7 K to 125.6 K (-8.11 %) |
Nov 14 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.63 | 6,250 | 110,188 | 136,670 | 130.4 K to 136.7 K (+4.79 %) |
Nov 14 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 11,200 | 196,336 | 130,420 | 119.2 K to 130.4 K (+9.39 %) |
Nov 14 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 4,500 | 0 | 28,644 | 33.1 K to 28.6 K (-13.58 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Grant | A | 158.30 | 3,185 | 504,186 | 37,427 | 34.2 K to 37.4 K (+9.30 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Grant | A | 158.30 | 18,559 | 2,937,890 | 87,370 | 68.8 K to 87.4 K (+26.97 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Grant | A | 158.30 | 46,684 | 7,390,077 | 659,838 | 613.2 K to 659.8 K (+7.61 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Grant | A | 158.30 | 3,185 | 504,186 | 39,760 | 36.6 K to 39.8 K (+8.71 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Grant | A | 158.30 | 19,809 | 3,135,765 | 119,220 | 99.4 K to 119.2 K (+19.93 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Grant | A | 158.30 | 20,763 | 3,286,783 | 218,463 | 197.7 K to 218.5 K (+10.50 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Grant | A | 158.30 | 3,185 | 504,186 | 80,925 | 77.7 K to 80.9 K (+4.10 %) |
Aug 26 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Grant | A | 158.30 | 3,185 | 504,186 | 279,120 | 275.9 K to 279.1 K (+1.15 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 24,944 | 0 | 33,144 | 8.2 K to 33.1 K (+304.20 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 24,944 | 0 | 275,935 | 300.9 K to 275.9 K (-8.29 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 200,000 | 0 | 300,879 | 500.9 K to 300.9 K (-39.93 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 1,290 | 0 | 0 | 1.3 K to 0 (-100.00 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 645 | 0 | 38,390 | 39 K to 38.4 K (-1.65 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 1,290 | 0 | 39,035 | 40.3 K to 39 K (-3.20 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 2,580 | 0 | 40,325 | 42.9 K to 40.3 K (-6.01 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 645 | 0 | 42,905 | 43.6 K to 42.9 K (-1.48 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 1,290 | 0 | 43,550 | 44.8 K to 43.6 K (-2.88 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 1,935 | 0 | 44,840 | 46.8 K to 44.8 K (-4.14 %) |
Aug 19 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 3,225 | 0 | 46,775 | 50 K to 46.8 K (-6.45 %) |
Jul 03 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 123.35 | 1,971 | 243,123 | 99,411 | 101.4 K to 99.4 K (-1.94 %) |
Jul 03 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 123.35 | 2,458 | 303,194 | 197,700 | 200.2 K to 197.7 K (-1.23 %) |
Jul 03 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 123.35 | 8,253 | 1,018,008 | 613,154 | 621.4 K to 613.2 K (-1.33 %) |
Jul 03 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 123.35 | 1,243 | 153,324 | 68,811 | 70.1 K to 68.8 K (-1.77 %) |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 18.87 | 65,625 | 1,238,344 | 0 | |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 18.87 | 33,750 | 636,863 | 0 | |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 122.38 | 1,000 | 122,380 | 621,407 | 622.4 K to 621.4 K (-0.16 %) |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 123.13 | 32,857 | 4,045,682 | 622,407 | 655.3 K to 622.4 K (-5.01 %) |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 123.87 | 19,200 | 2,378,304 | 655,264 | 674.5 K to 655.3 K (-2.85 %) |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 18.87 | 65,625 | 1,238,344 | 674,464 | 608.8 K to 674.5 K (+10.78 %) |
Jun 30 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 18.87 | 33,750 | 636,863 | 608,839 | 575.1 K to 608.8 K (+5.87 %) |
Jun 17 2014 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Payment of Exercise | F | 113.80 | 1,850 | 210,530 | 36,575 | 38.4 K to 36.6 K (-4.81 %) |
Jun 17 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Payment of Exercise | F | 113.80 | 1,439 | 163,758 | 77,740 | 79.2 K to 77.7 K (-1.82 %) |
May 20 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | S | 105.67 | 900 | 95,103 | 70,054 | 71 K to 70.1 K (-1.27 %) |
Apr 24 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 112.54 | 1,800 | 202,572 | 79,179 | 81 K to 79.2 K (-2.22 %) |
Apr 24 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 111.30 | 3,300 | 367,290 | 80,979 | 84.3 K to 81 K (-3.92 %) |
Apr 24 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 110.22 | 6,430 | 708,715 | 84,279 | 90.7 K to 84.3 K (-7.09 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Grant | A | 100.66 | 3,185 | 320,602 | 34,242 | 31.1 K to 34.2 K (+10.26 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Grant | A | 100.66 | 19,809 | 1,993,974 | 101,382 | 81.6 K to 101.4 K (+24.28 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Grant | A | 100.66 | 3,185 | 320,602 | 90,709 | 87.5 K to 90.7 K (+3.64 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Grant | A | 100.66 | 18,559 | 1,868,149 | 70,954 | 52.4 K to 71 K (+35.42 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Grant | A | 100.66 | 73,684 | 7,417,031 | 575,089 | 501.4 K to 575.1 K (+14.70 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Grant | A | 100.66 | 20,763 | 2,090,004 | 200,158 | 179.4 K to 200.2 K (+11.57 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Grant | A | 100.66 | 3,185 | 320,602 | 463,779 | 460.6 K to 463.8 K (+0.69 %) |
Apr 21 2014 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Grant | A | 100.66 | 3,185 | 320,602 | 38,425 | 35.2 K to 38.4 K (+9.04 %) |
Mar 06 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 240 | 0 | 460,594 | 460.8 K to 460.6 K (-0.05 %) |
Mar 06 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 112.20 | 10,000 | 1,122,000 | 460,834 | 470.8 K to 460.8 K (-2.12 %) |
Mar 06 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | S | 110.66 | 1,319 | 145,961 | 52,395 | 53.7 K to 52.4 K (-2.46 %) |
Feb 19 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 400,000 | 0 | 400,000 | 0 to 400 K |
Feb 19 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 400,000 | 0 | 501,405 | 901.4 K to 501.4 K (-44.38 %) |
Feb 10 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Option Exercise | M | 18.87 | 22,500 | 424,649 | 0 | |
Feb 10 2014 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Buy | M | 18.87 | 22,500 | 424,649 | 470,834 | 448.3 K to 470.8 K (+5.02 %) |
Jan 28 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Gift | G | 0.00 | 10,450 | 0 | 10,450 | 0 to 10.5 K |
Jan 28 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Gift | G | 0.00 | 10,450 | 0 | 87,524 | 98 K to 87.5 K (-10.67 %) |
Jan 14 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Option Exercise | M | 18.87 | 22,500 | 424,575 | 0 | |
Jan 14 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 92.85 | 50 | 4,643 | 97,974 | 98 K to 98 K (-0.05 %) |
Jan 14 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 91.83 | 12,000 | 1,101,960 | 98,024 | 110 K to 98 K (-10.91 %) |
Jan 14 2014 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | M | 18.87 | 22,500 | 424,575 | 110,024 | 87.5 K to 110 K (+25.71 %) |
Jan 13 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 18.87 | 30,001 | 566,218 | 0 | |
Jan 13 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 91.44 | 27,601 | 2,523,835 | 179,395 | 207 K to 179.4 K (-13.33 %) |
Jan 13 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 91.95 | 2,400 | 220,680 | 206,996 | 209.4 K to 207 K (-1.15 %) |
Jan 13 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 18.87 | 30,001 | 566,218 | 209,396 | 179.4 K to 209.4 K (+16.72 %) |
Jan 10 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 8,000 | 140,240 | 11,200 | |
Jan 10 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 90.06 | 8,000 | 720,480 | 81,573 | 89.6 K to 81.6 K (-8.93 %) |
Jan 10 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 8,000 | 140,240 | 89,573 | 81.6 K to 89.6 K (+9.81 %) |
Jan 09 2014 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Option Exercise | M | 18.87 | 22,500 | 424,649 | 0 | |
Jan 09 2014 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Sell | S | 88.31 | 22,500 | 1,986,975 | 35,240 | 57.7 K to 35.2 K (-38.97 %) |
Jan 09 2014 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Buy | M | 18.87 | 22,500 | 424,649 | 57,740 | 35.2 K to 57.7 K (+63.85 %) |
Jan 09 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | S | 88.31 | 8,463 | 747,368 | 53,714 | 62.2 K to 53.7 K (-13.61 %) |
Jan 06 2014 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 89.94 | 8,851 | 796,059 | 81,573 | 90.4 K to 81.6 K (-9.79 %) |
Jan 06 2014 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 89.94 | 4,547 | 408,957 | 62,177 | 66.7 K to 62.2 K (-6.81 %) |
Jan 06 2014 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 89.94 | 34,055 | 3,062,907 | 901,405 | 935.5 K to 901.4 K (-3.64 %) |
Jan 06 2014 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 89.94 | 9,135 | 821,602 | 179,395 | 188.5 K to 179.4 K (-4.85 %) |
Dec 09 2013 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Gift | G | 0.00 | 200 | 0 | 35,240 | 35.4 K to 35.2 K (-0.56 %) |
Nov 25 2013 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 6,000 | 0 | 448,334 | 454.3 K to 448.3 K (-1.32 %) |
Jul 26 2013 | SLXP | SALIX PHARMACEUTIC ... | Bertrand William C JR | Gen Counsel&VP Corp ... | Grant | A | 0.00 | 14,428 | 0 | 14,428 | 0 to 14.4 K |
Jul 26 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 12,000 | 210,360 | 19,200 | |
Jul 26 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 71.88 | 3,000 | 215,640 | 90,424 | 93.4 K to 90.4 K (-3.21 %) |
Jul 26 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 70.96 | 6,000 | 425,760 | 93,424 | 99.4 K to 93.4 K (-6.03 %) |
Jul 26 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 69.91 | 3,000 | 209,730 | 99,424 | 102.4 K to 99.4 K (-2.93 %) |
Jul 26 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 12,000 | 210,360 | 102,424 | 90.4 K to 102.4 K (+13.27 %) |
Jul 03 2013 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 66.15 | 6,362 | 420,846 | 188,530 | 194.9 K to 188.5 K (-3.26 %) |
Jul 03 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Payment of Exercise | F | 66.15 | 4,835 | 319,835 | 90,424 | 95.3 K to 90.4 K (-5.08 %) |
Jul 03 2013 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 66.15 | 20,113 | 1,330,475 | 935,460 | 955.6 K to 935.5 K (-2.10 %) |
Jul 03 2013 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Payment of Exercise | F | 66.15 | 3,196 | 211,415 | 66,724 | 69.9 K to 66.7 K (-4.57 %) |
Jun 24 2013 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 247,761 | 0 | 955,573 | 707.8 K to 955.6 K (+35.00 %) |
Jun 24 2013 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 400,000 | 0 | 0 | 400 K to 0 (-100.00 %) |
Jun 17 2013 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Payment of Exercise | F | 65.04 | 1,872 | 121,755 | 35,440 | 37.3 K to 35.4 K (-5.02 %) |
Jun 17 2013 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Payment of Exercise | F | 65.04 | 1,040 | 67,642 | 87,524 | 88.6 K to 87.5 K (-1.17 %) |
May 07 2013 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Sell | S | 54.00 | 2,008 | 108,432 | 31,057 | 33.1 K to 31.1 K (-6.07 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Grant | A | 48.70 | 21,354 | 1,039,940 | 69,920 | 48.6 K to 69.9 K (+43.97 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Grant | A | 48.70 | 24,421 | 1,189,303 | 194,892 | 170.5 K to 194.9 K (+14.33 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Grant | A | 48.70 | 94,199 | 4,587,491 | 707,812 | 613.6 K to 707.8 K (+15.35 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Grant | A | 48.70 | 23,741 | 1,156,187 | 95,259 | 71.5 K to 95.3 K (+33.20 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Grant | A | 48.70 | 4,110 | 200,157 | 454,334 | 450.2 K to 454.3 K (+0.91 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Grant | A | 48.70 | 4,110 | 200,157 | 88,564 | 84.5 K to 88.6 K (+4.87 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Grant | A | 48.70 | 4,110 | 200,157 | 33,065 | 29 K to 33.1 K (+14.19 %) |
Apr 22 2013 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Grant | A | 48.70 | 4,110 | 200,157 | 37,312 | 33.2 K to 37.3 K (+12.38 %) |
Apr 17 2013 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Option Exercise | M | 15.25 | 30,000 | 457,398 | 0 | |
Apr 17 2013 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Sell | S | 49.44 | 30,000 | 1,483,200 | 33,202 | 63.2 K to 33.2 K (-47.47 %) |
Apr 17 2013 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Buy | M | 15.25 | 30,000 | 457,398 | 63,202 | 33.2 K to 63.2 K (+90.36 %) |
Apr 12 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Option Exercise | M | 17.53 | 13,000 | 227,890 | 31,200 | |
Apr 12 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Sell | S | 49.37 | 8,673 | 428,186 | 71,518 | 80.2 K to 71.5 K (-10.82 %) |
Apr 12 2013 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | EVP Research&Devel ... | Buy | M | 17.53 | 13,000 | 227,890 | 80,191 | 67.2 K to 80.2 K (+19.35 %) |
Apr 10 2013 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Option Exercise | M | 7.60 | 15,000 | 114,000 | 0 | |
Apr 10 2013 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 50.26 | 1,079 | 54,231 | 84,454 | 85.5 K to 84.5 K (-1.26 %) |
Apr 10 2013 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Sell | S | 49.43 | 5,107 | 252,439 | 85,533 | 90.6 K to 85.5 K (-5.63 %) |
Apr 10 2013 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | M | 7.60 | 15,000 | 114,000 | 90,640 | 75.6 K to 90.6 K (+19.83 %) |
Mar 08 2013 | SLXP | SALIX PHARMACEUTIC ... | Scruggs Rick D | Executive Vice Pres ... | Sell | S | 49.69 | 2,000 | 99,380 | 48,566 | 50.6 K to 48.6 K (-3.96 %) |